Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
Overcoming endocrine resistance in breast cancer
Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype.
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …
Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing …
Importance Approximately 25% of patients with early-stage breast cancer who receive (neo)
adjuvant chemotherapy experience a recurrence within 5 years. Improvements in therapy …
adjuvant chemotherapy experience a recurrence within 5 years. Improvements in therapy …
Extracellular matrix in the tumor microenvironment and its impact on cancer therapy
E Henke, R Nandigama, S Ergün - Frontiers in molecular biosciences, 2020 - frontiersin.org
Solid tumors are complex organ-like structures that consist not only of tumor cells but also of
vasculature, extracellular matrix (ECM), stromal, and immune cells. Often, this tumor …
vasculature, extracellular matrix (ECM), stromal, and immune cells. Often, this tumor …
[HTML][HTML] Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors
V Leko, SA Rosenberg - Cancer Cell, 2020 - cell.com
Cancer elimination in humans can be achieved with immunotherapy that relies on T
lymphocyte-mediated recognition of tumor antigens. Several types of these antigens have …
lymphocyte-mediated recognition of tumor antigens. Several types of these antigens have …
Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis
Importance Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1)
inhibitors have been increasingly used in cancer therapy. Understanding the treatment …
inhibitors have been increasingly used in cancer therapy. Understanding the treatment …
T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab …
PURPOSE Biomarkers that can predict response to anti–programmed cell death 1 (PD-1)
therapy across multiple tumor types include a T-cell–inflamed gene-expression profile …
therapy across multiple tumor types include a T-cell–inflamed gene-expression profile …
Myeloid-derived suppressor cells as a therapeutic target for cancer
The emergence of immunotherapy has been an astounding breakthrough in cancer
treatments. In particular, immune checkpoint inhibitors, targeting PD-1 and CTLA-4, have …
treatments. In particular, immune checkpoint inhibitors, targeting PD-1 and CTLA-4, have …
Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor
V Scabia, A Ayyanan, F De Martino, A Agnoletto… - Nature …, 2022 - nature.com
Estrogen and progesterone receptor (ER, PR) signaling control breast development and
impinge on breast carcinogenesis. ER is an established driver of ER+ disease but the role of …
impinge on breast carcinogenesis. ER is an established driver of ER+ disease but the role of …
Immunotherapy and targeted therapy combinations in metastatic breast cancer
Immunotherapy is emerging as a new treatment modality in breast cancer. After long-
standing use of endocrine therapy and targeted biological therapy, improved understanding …
standing use of endocrine therapy and targeted biological therapy, improved understanding …